Literature DB >> 12457050

Aortic valve replacement in the elderly: frequently indicated yet frequently denied.

Katrina A Bramstedt1.   

Abstract

BACKGROUND: The prevalence of aortic stenosis is nearly 20% in octogenarians. Aortic valve replacement (AVR) is the optimal therapy choice, yet many symptomatic patients are denied this beneficent technology. Whether mechanical or bioprosthetic, aortic valves are not a scarce resource and their safety, effectiveness and longevity are proven.
OBJECTIVE: Because the geriatric population is soaring, clinicians will be encountering more cases of aortic stenosis and the decision-making that leads to surgical referral or non-referral warrants exploration.
METHODS: A literature review was conducted to explore the notion that physicians deny AVR to their patients based solely on their chronological age value.
RESULTS: Using age as the sole exclusion criterion, medical literature documents the fact that AVR is frequently denied to the elderly.
CONCLUSION: It appears that AVR is another beneficent cardiac technology that has been added to the age discrimination list, even though the devices are not scarce, they are cost-effective, and they can improve the life of a symptomatic elderly patient. There is no ethical justification for denying AVR to clinically suitable elderly candidates who request such therapy. Copyright 2003 S. Karger AG, Basel

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health

Mesh:

Year:  2003        PMID: 12457050     DOI: 10.1159/000066502

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  11 in total

Review 1.  Which strategy for a protein crystallization project?

Authors:  C E Kundrot
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

2.  Risk profile and outcomes of aortic valve replacement in octogenarians.

Authors:  Sujatha Kesavan; Aamer Iqbal; Yusra Khan; Jonathan Hutter; Katie Pike; Chris Rogers; Mark Turner; Mandie Townsend; Andreas Baumbach
Journal:  World J Cardiol       Date:  2011-11-26

3.  Vascular access site complications after percutaneous transfemoral aortic valve implantation.

Authors:  Philipp Kahlert; Fadi Al-Rashid; Marcel Weber; Daniel Wendt; Torsten Heine; Eva Kottenberg; Matthias Thielmann; Hilmar Kühl; Jürgen Peters; Heinz G Jakob; Stefan Sack; Raimund Erbel; Holger Eggebrecht
Journal:  Herz       Date:  2009-08       Impact factor: 1.443

Review 4.  [Transcatheter-based aortic valve implantation. Present and future technologies].

Authors:  Stefan Sack; Joachim Schofer
Journal:  Herz       Date:  2009-08       Impact factor: 1.443

5.  Apico-Aortic Conduit for severe aortic stenosis: Technique, applications, and systematic review.

Authors:  Elsayed Elmistekawy; Harry Lapierre; Thierry Mesana; Marc Ruel
Journal:  J Saudi Heart Assoc       Date:  2010-07-07

Review 6.  [Percutaneous aortic valve implantation - contra].

Authors:  Klaus Kallenbach; Matthias Karck
Journal:  Herz       Date:  2009-03       Impact factor: 1.443

7.  Urochordates carry multiple genes for goose-type lysozyme and no genes for chicken- or invertebrate-type lysozymes.

Authors:  I W Nilsen; B Myrnes; R B Edvardsen; D Chourrout
Journal:  Cell Mol Life Sci       Date:  2003-10       Impact factor: 9.261

8.  Sea urchin elongation factor 1delta (EF1delta) and evidence for cell cycle-directed localization changes of a sub-fraction of the protein at M phase.

Authors:  S Boulben; A Monnier; M Le Breton; J Morales; P Cormier; R Bellé; O Mulner-Lorillon
Journal:  Cell Mol Life Sci       Date:  2003-10       Impact factor: 9.261

9.  Cardiac anesthesia and surgery in geriatric patients: epidemiology, current surgical outcomes, and future directions.

Authors:  J G Castillo; G Silvay; J Chikwe
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2009

10.  Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium.

Authors:  Martin B Leon; Nicolo Piazza; Eugenia Nikolsky; Eugene H Blackstone; Donald E Cutlip; Arie Pieter Kappetein; Mitchell W Krucoff; Michael Mack; Roxana Mehran; Craig Miller; Marie-Angèle Morel; John Petersen; Jeffrey J Popma; Johanna J M Takkenberg; Alec Vahanian; Gerrit-Anne van Es; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys
Journal:  Eur Heart J       Date:  2011-01-06       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.